Berenberg Bank Lowers Reckitt Benckiser (RB) Price Target to GBX 7,300

Reckitt Benckiser (LON:RB) had its price target cut by Berenberg Bank from GBX 7,500 ($104.60) to GBX 7,300 ($101.81) in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price target points to a potential upside of 31.98% from the stock’s current price.

A number of other research firms also recently issued reports on RB. Liberum Capital reiterated a “buy” rating and issued a GBX 8,000 ($111.58) target price on shares of Reckitt Benckiser in a research report on Monday, February 19th. Goldman Sachs set a GBX 6,910 ($96.37) target price on shares of Reckitt Benckiser and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Societe Generale set a GBX 6,500 ($90.66) price target on shares of Reckitt Benckiser and gave the stock a “buy” rating in a research note on Thursday, March 22nd. UBS set a GBX 7,000 ($97.63) price target on shares of Reckitt Benckiser and gave the stock a “neutral” rating in a research note on Thursday, January 11th. Finally, Investec upgraded shares of Reckitt Benckiser to a “hold” rating and dropped their price target for the stock from GBX 6,400 ($89.26) to GBX 6,000 ($83.68) in a research note on Tuesday, February 20th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Reckitt Benckiser presently has an average rating of “Hold” and an average price target of GBX 7,155.83 ($99.80).

How to Become a New Pot Stock Millionaire

RB stock opened at GBX 5,531 ($77.14) on Tuesday. Reckitt Benckiser has a 12-month low of GBX 5,562 ($77.57) and a 12-month high of GBX 8,110.43 ($113.12).

TRADEMARK VIOLATION WARNING: “Berenberg Bank Lowers Reckitt Benckiser (RB) Price Target to GBX 7,300” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/24/berenberg-bank-lowers-reckitt-benckiser-rb-price-target-to-gbx-7300.html.

Reckitt Benckiser Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Analyst Recommendations for Reckitt Benckiser (LON:RB)

Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply